Ligand Pharmaceuticals | LGND - Beneficio Bruto En Ventas

Precio De Mercado
200.36
Cambio Diario
-4.45 -2.17%
Mensual
6.01%
Anual
79.42%
Q1 Expectativa
198.67




Beneficio Bruto En Ventas Cambio Fecha
Agenus USD 34.2M 4.61M 2025-12
Amgen USD 6.48B 307M 2025-09
Anika Therapeutics USD 19.18M 3.6M 2025-12
Arrowhead Research USD 256.47M 228.7M 2025-09
Baxter International USD 577M 373M 2025-12
Bristol-Myers Squibb USD 8.79B 110M 2025-09
Eli Lilly USD 14.59B 1.48B 2025-09
Enanta Pharmaceuticals -22.29M 23.75M 2024-12
Enviri Corporation USD 83.01M 37.46M 2025-12
Gilead Sciences USD 6.31B 106M 2025-12
GlaxoSmithKline GBP 6.18B 106M 2025-12
Glaxosmithkline GBP 8.75B 2.92B 2025-09
Heron Therapeutics USD 29.47M 3.17M 2025-12
Insmed USD 217.69M 106.25M 2025-12
Intrexon USD -297K 167K 2024-06
Ionis Pharmaceuticals USD 195M 40M 2025-12
Karyopharm Therapeutics USD -30.78M 1.29M 2024-12
Ligand Pharmaceuticals USD 155.28M 82.42M 2025-09
MacroGenics USD 31.11M 30.14M 2025-12
Merck USD 13.42B 431M 2025-09
Pacira USD 142.25M 11.34M 2025-12
Pfizer USD 3.54B 7.61B 2025-09
Rigel Pharmaceuticals USD 28.49M 7.01M 2024-06
Sangamo BioSciences -2.39M 1.09M 2024-06
Veracyte USD 101.97M 10.69M 2025-12